Although surgery is the only therapeutic means of cure, less than 20% are found fit to undergo resection, primarily due to late diagnosis of the disease. This is where Trovera – built upon TrovaGene’s Precision Cancer Monitoring (PCM) platform – has significant utility as it can rapidly detect KRAS gene mutation, which occurs in almost 90% of pancreatic carcinomas.
Moreover, according to Diane Simeone, M.D., director of the Pancreatic Cancer Center at the University of Michigan Comprehensive Cancer Center, “The Trovagene assay will allow us to quickly test multiple therapies to determine which one will be most effective in treating an individual patient's tumor."
The latest collaboration reflects TrovaGene’s focus on expanding the market opportunity for Trovera. The University of Michigan Cancer Center is one of only 45 centers in the U.S. to earn the National Cancer Institute's most coveted "comprehensive" designation. The University of Michigan is also one of the best hospitals in the U.S. for cancer treatment.
Bids are Coming in!
Shorts have 12 Days to Cover and I Feel they're Under Estimating the Potential of TROV!
Once this Gets Lit this will Run Hard!
This MU Partnership is such a Big Deal!
The Street will come Around Soon!
Can't be Ignored!
It will Happen in One Final Push!
Stops Getting Hit!
Nothing But Positive Karma Around TROV!
News Cycle has been Great!
Just Let it do its Thing!
That's Why James Altucher said he won't sell Until $70
Article: June 2016
Tutes Hold 10.5m Shrs!
Shorts Hold 4.7m Shrs!
Float Only 22.9m Shrs!
Retail Shrs Holders?
TROV a Screaming Buy Now!
It Never Looked So Bullish!